Evaxion A (EVAX) Asset Utilization Ratio (2025 - 2026)
Evaxion A (EVAX) posted Asset Utilization Ratio of 1422.0 for Q1 2026, up 11.71% on a QoQ basis from 1272.94 in Q4 2025, and up 814407.2% year-over-year from N/an in Q1 2025.
Evaxion A (EVAX) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Evaxion A's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 1422.0 for Q1 2026.
- Quarterly Asset Utilization Ratio rose 814407.2% year-over-year to 1422.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1422.0 (up 814407.2% YoY) and the FY2025 annual result came in at 0.37, up 39.69% from the prior year.
- Asset Utilization Ratio was 1422.0 for Q1 2026 at Evaxion A, up from 1272.94 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 1551.88 in Q2 2025 and bottomed at 0.17 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Evaxion A | 25.44 Mn | 25.44 Mn | - | 1,422.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,422.00 |
| Dec 31, 2025 | 1,272.94 |
| Sep 30, 2025 | 1,418.30 |
| Jun 30, 2025 | 1,551.88 |
| Mar 31, 2025 | 0.17 |